Journal of Clinical Oncology
Vol. 43, Issue 36
Issue 36
2025
12
Articles
Articles in this Issue
Challenges Remaining for Yttrium-90 Radioembolization: The Case for Standardized Dosimetry and Comparative Local Control Analyses in Liver Tumors
Christopher H. Crane, Theodore S. Hong, Freddy E. Escorcia et al.
Dec 20, 2025
pp. 3783-3787
10.1200/jco-25-01376
Sun Sets on Rituximab/Gemcitabine/Oxaliplatin as Bispecific Antibodies Rise: The SUNMO Trial
Danielle S. Wallace, Jonathan W. Friedberg
Dec 20, 2025
pp. 3778-3782
10.1200/jco-25-02197
<sup>177</sup> Lu-Prostate-Specific Membrane Antigen Neoadjuvant to Stereotactic Ablative Radiotherapy for Oligorecurrent Prostate Cancer (LUNAR): An Open-Label, Randomized, Controlled, Phase II Study
Amar U. Kishan, Luca F. Valle, Holly Wilhalme et al.
Dec 20, 2025
pp. 3812-3821
10.1200/jco-25-01553
PURPOSE Progression after metastasis-directed therapy via stereotactic body radiotherapy (SBRT) for oligorecurrent hormone-sensitive prostate cancer (orHSPC) is common. We aimed to...
Erratum: Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Systemic Cancer Therapy: ASCO Guideline Update
William Dale, Heidi D. Klepin, Grant R. Williams et al.
Dec 20, 2025
pp. 3850-3850
10.1200/jco-25-02598
Efficacy and Safety of Glofitamab Plus Polatuzumab Vedotin in Relapsed/Refractory Large B-Cell Lymphoma Including High-Grade B-Cell Lymphoma: Results From a Phase Ib/II Trial
Martin Hutchings, Anna Sureda, Francesc Bosch et al.
Dec 20, 2025
pp. 3788-3798
10.1200/jco-25-00992
PURPOSE An unmet need remains for more effective therapies for relapsed/refractory (R/R) large B-cell lymphoma (LBCL), especially high-grade B-cell lymphoma...
Impact of Pulmonary Tumor Burden in Favorable Histology Wilms Tumor Outcomes: A Report From the Children's Oncology Group Study AREN0533
David B. Dix, Geetika Khanna, Lindsay A. Renfro et al.
Dec 20, 2025
pp. 3822-3832
10.1200/jco-25-00532
PURPOSE Children with favorable histology Wilms tumor (FHWT) with pulmonary metastases have inferior outcomes compared with those with localized disease. We evaluated the impact of...
Antibody-Drug Conjugates and Bispecific Antibodies for Lymphoma: Partners of Convenience or a Perfect Match
Michael John Dickinson
Dec 20, 2025
pp. 3775-3777
10.1200/jco-25-02200
Mosunetuzumab Plus Polatuzumab Vedotin in Transplant-Ineligible Refractory/Relapsed Large B-Cell Lymphoma: Primary Results of the Phase III SUNMO Trial
Lihua E. Budde, Won-Seog Kim, Eduardo M. Rego et al.
Dec 20, 2025
pp. 3799-3811
10.1200/jco-25-01957
PURPOSE Prognosis for patients with refractory/relapsed large B-cell lymphoma (LBCL) considered ineligible for curative-intent therapy is poor. The combination of mosunetuzumab, a...
The Man at the Bow
Alexis Drutchas
Dec 20, 2025
pp. 3844-3845
10.1200/jco-25-01442
Investigation of DNA Damage Response Genes Validates the Role of DNA Repair in Pediatric Cancer Risk and Identifies <i>SMARCAL1</i> as a Novel Osteosarcoma Predisposition Gene
Ninad Oak, Wenan Chen, Alise Blake et al.
Dec 20, 2025
pp. 3833-3843
10.1200/jco-25-01114
PURPOSE Recent studies reveal that 5%-18% of children with cancer harbor pathogenic variants in known cancer-predisposing genes. However, DNA damage repair (DDR) genes, which are f...
Reply to: Decoding the End Points of Poly (ADP-ribose) Polymerase Inhibitor Trials in Ovarian Cancer
Mirat Shah, Mallorie H. Fiero, Joyce Cheng et al.
Dec 20, 2025
pp. 3847-3849
10.1200/jco-25-01933
Decoding the End Points of Poly (ADP-ribose) Polymerase Inhibitor Trials in Ovarian Cancer
Bradley J. Monk, Robert L. Coleman, David M. O'Malley et al.
Dec 20, 2025
pp. 3846-3847
10.1200/jco-25-01721
All Issues
Issue 9
- Issue 9
14
Issue 8
- Issue 8
16
Issue 7_suppl
- Issue 7_suppl
886
Issue 7
- Issue 7
17
Issue 6
- Issue 6
15
Issue 5
- Issue 5
15
Issue 4
- Issue 4
13
Issue 3
- Issue 3
13
Issue 24
- Issue 24
18
Issue 23
- Issue 23
16
Issue 22
- Issue 22
15
Issue 21
- Issue 21
14
Issue 20
- Issue 20
18
Issue 2_suppl
- Issue 2_suppl
818
Issue 2
- Issue 2
12
Issue 19_suppl
- Issue 19_suppl
340
Issue 19
- Issue 19
16
Issue 18
- Issue 18
16
Issue 17_suppl
- Issue 17_suppl
60
Issue 17
- Issue 17
17
Issue 16_suppl
- Issue 16_suppl
7213
Issue 16
- Issue 16
15
Issue 15
- Issue 15
13
Issue 14
- Issue 14
14
Issue 13
- Issue 13
14
Issue 12
- Issue 12
16
Issue 11
- Issue 11
15
Issue 10
- Issue 10
14
Issue 1
- Issue 1
11
Issue 9
- Issue 9
15
Issue 8
- Issue 8
19
Issue 7
- Issue 7
19
Issue 6
- Issue 6
20
Issue 5_suppl
- Issue 5_suppl
869
Issue 5
- Issue 5
21
Issue 4_suppl
- Issue 4_suppl
824
Issue 4
- Issue 4
18
Issue 36
- Issue 36
12
Issue 35
- Issue 35
12
Issue 34
- Issue 34
12
Issue 33
- Issue 33
14
Issue 32
- Issue 32
17
Issue 31
- Issue 31
16
Issue 30
- Issue 30
14
Issue 3
- Issue 3
17
Issue 29
- Issue 29
16
Issue 28
- Issue 28
16
Issue 27
- Issue 27
14
Issue 26
- Issue 26
13
Issue 25
- Issue 25
17
Issue 24
- Issue 24
19
Issue 23
- Issue 23
14
Issue 22
- Issue 22
14
Issue 21
- Issue 21
13
Issue 20
- Issue 20
12
Issue 2
- Issue 2
18
Issue 19
- Issue 19
12
Issue 18
- Issue 18
14
Issue 17_suppl
- Issue 17_suppl
57
Issue 17
- Issue 17
15
Issue 16_suppl
- Issue 16_suppl
6439
Issue 16
- Issue 16
14
Issue 15
- Issue 15
16
Issue 14
- Issue 14
17
Issue 13
- Issue 13
17
Issue 12
- Issue 12
15
Issue 11
- Issue 11
18
Issue 10
- Issue 10
14
Issue 1
- Issue 1
20
Journal Info
Publisher
Lippincott Williams & Wilkins
ISSN
0732-183X
E-ISSN
1527-7755
Subject
Health Sciences
Language
English